About raysearch laboratories - RSLBF
RaySearch Laboratories AB is a medical technology company, which engages in the development of software solutions for improved radiation therapy of cancer. Its products and services are divided into three categories: RayStation, Partner Products, and Research. RayStation is the company's proprietary treatment planning system. Partner Products include proton and intensity modulated radiation therapy, automatic treatment planning, quality assurance, and radiobiology. Research offers long term study of new methods and techniques in radiation treatment. The company was founded by Johan Löf, Erik Hedlund, Carl Filip Bergendal, Anders Brahme, Bengt Lind, and Anders Liander in 2000 and is headquartered in Stockholm, Sweden.
RSLBF At a Glance
RaySearch Laboratories AB
Eugeniavägen 18
Stockholm, Stockholm 103 65
| Phone | 46-8-510-530-00 | Revenue | 112.75M | |
| Industry | Packaged Software | Net Income | 19.25M | |
| Sector | Technology Services | 2024 Sales Growth | 17.095% | |
| Fiscal Year-end | 12 / 2025 | Employees | 408 | |
| View SEC Filings |
RSLBF Valuation
| P/E Current | 53.619 |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | 34.815 |
| Price to Sales Ratio | 5.944 |
| Price to Book Ratio | 8.446 |
| Price to Cash Flow Ratio | 14.603 |
| Enterprise Value to EBITDA | 12.985 |
| Enterprise Value to Sales | 5.952 |
| Total Debt to Enterprise Value | 0.064 |
RSLBF Efficiency
| Revenue/Employee | 276,337.281 |
| Income Per Employee | 47,178.575 |
| Receivables Turnover | 2.661 |
| Total Asset Turnover | 0.589 |
RSLBF Liquidity
| Current Ratio | 1.399 |
| Quick Ratio | 1.384 |
| Cash Ratio | 0.657 |
RSLBF Profitability
| Gross Margin | 66.70 |
| Operating Margin | 20.72 |
| Pretax Margin | 22.052 |
| Net Margin | 17.073 |
| Return on Assets | 10.051 |
| Return on Equity | 25.277 |
| Return on Total Capital | 15.77 |
| Return on Invested Capital | 16.673 |
RSLBF Capital Structure
| Total Debt to Total Equity | 53.83 |
| Total Debt to Total Capital | 34.993 |
| Total Debt to Total Assets | 22.568 |
| Long-Term Debt to Equity | 45.038 |
| Long-Term Debt to Total Capital | 29.278 |